News-Medical.Net on MSN

New diagnostic framework addresses challenges of rapidly-mutating RNA viruses

The rapid evolutionary dynamics of RNA viruses, driven by high mutation rates and the consequent formation of complex quasispecies populations, present a formidable obstacle to conventional molecular ...

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ...

Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared ...

NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise

The Company believes Mr. Gabbai’s experience in healthcare leadership, capital markets, and with global investors will be valuable as NurExone advances its preclinical programs toward first-in-human ...

NurExone Biologic Inc: NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company") today announced changes to its board of directors ...